Home/Pipeline/AI Programme - RSV

AI Programme - RSV

Respiratory Syncytial Virus (RSV)

DiscoveryActive - Target/Candidate ID

Key Facts

Indication

Respiratory Syncytial Virus (RSV)

Phase

Discovery

Status

Active - Target/Candidate ID

Company

Poolbeg Pharma

About Poolbeg Pharma

Poolbeg Pharma is a UK-based, AIM-listed biotech founded in 2021 with a mission to develop high-value therapies for large markets with unmet needs. Its strategy centers on a capital-efficient model of de-risking assets through early clinical development before pursuing partnerships. Key achievements include securing FDA Orphan Drug Designation for its lead oncology asset, POLB 001, and building a proprietary AI discovery platform powered by unique human challenge trial data. The company aims to accelerate pipeline growth while minimizing substantial capital expenditure.

View full company profile

Therapeutic Areas

Oncology Supportive Care Metabolic Disease (Obesity)Infectious Disease

Other Respiratory Syncytial Virus (RSV) Drugs

Drug	Company	Phase	Status
IN-002	Inhalon Biopharma	Pre-IND	Active
BLB201	CyanVac	Phase 1/2	Active
Oral RSV Vaccine	Vaxart	Preclinical/Phase 1	Active